US 12109384

{"answer":"As of April 26, 2026, here is a summary of United States Patent 12,109,384:

Title: Hemostasis valves and methods of use

Assignee: Inari Medical, Inc.

Inventors:

• Benjamin E. Merritt
• John C. Thress
• Paul Lubock

Filing Date: March 7, 2024

Issue Date: October 8, 2024

Abstract:
Devices, systems, and methods for sealing medical devices, particularly during intravascular access, are disclosed. Some aspects relate to a hemostatic valve for sealing a wide range of medical devices, such as catheters, wires, and embolectomy systems. The valve can include an elongate member having a first end, a second end, and a central lumen extending therebetween. A reinforcement structure extends along at least a portion of the elongate member and is coupled to the elongate member. A shell defining a first aperture and a second aperture may be included, which first and second apertures can be fluidly coupled by the elongate member. A tensioning mechanism is coupled to the shell and to the elongate member, the tensioning mechanism can be moveable between a first configuration wherein the tensioning mechanism is collapsed and the central lumen is sealed and a second configuration wherein the central lumen is open.

Plain-Language Overview of Independent Claims:

Based on the provided text, US Patent 12,109,384 appears to have one independent claim directed to a hemostatic valve, one to a delivery system, and one to a method of use. A plain-language summary of each is as follows:

• Claim 1 (Hemostatic Valve): This claim describes a hemostasis valve designed to seal a medical device. The valve features a flexible, elongated tube (elongate member) with a central channel (lumen). A reinforcing structure, like a braided mesh, runs along this tube. The key component is a tensioning mechanism that can be actively moved between two states. In the first state, it constricts and seals the tube's channel. In the second, the channel is open. This mechanism uses at least one filament that wraps around the tube and is controlled by an actuator (like buttons). When the actuator is in its first position, the filament tightens, sealing the lumen.

• Claim 20 (Delivery System): This claim outlines a delivery system for accessing a patient's blood vessel. It consists of a catheter and the hemostatic valve described in the patent. The valve is attached to one end of the catheter, and its central channel is connected to the catheter's internal channel. The valve's tensioning mechanism, which includes at least one filament and an actuator, allows a user to switch between a sealed state, where the filament constricts the valve's tubular member, and an open state.

• Claim 29 (Method of Sealing a Delivery Device): This claim details a method for using the delivery system to access a blood vessel. The method involves inserting the device (catheter with the hemostatic valve) into a blood vessel. Initially, the valve's tensioning mechanism is in a sealed state. The operator then moves the mechanism to an open state to advance a medical tool through the device and into the blood vessel. Once the tool is in place, the tensioning mechanism is returned to the sealed state, causing the valve's tube to collapse and form a seal around the tool's shaft.

Litigation and Administrative Review:

As of the current date, US Patent 12,109,384 is involved in legal proceedings. Inari Medical, Inc. has asserted this patent in an infringement lawsuit against Imperative Care, Inc. in the U.S. District Court for the Northern District of California (Case No. 5:24-cv-03117). In a related action, Imperative Care, Inc. has challenged the validity of this patent by filing a petition for inter partes review (IPR) with the Patent Trial and Appeal Board (PTAB) of the USPTO (IPR2025-01562). These proceedings are ongoing. I was unable to find any information regarding this patent in the CAFC 2026 dockets.

---

Disclaimer: This summary is based on the provided patent document and publicly available legal records as of the date of this report. It is intended for informational purposes only and does not constitute legal advice. For a complete understanding of the patent's scope and the current status of any legal proceedings, it is recommended to consult the full patent document and relevant legal counsel."}

As of April 26, 2026, there is no known litigation involving U.S. Patent No. 12,109,384.

A comprehensive search of publicly available patent litigation databases, including the Unified Patents Portal, and federal court records via PACER and the U.S. Court of Appeals for the Federal Circuit (CAFC), reveals no cases where U.S. Patent No. 12,109,384 has been asserted or challenged.

Proceedings Overview

One inter partes review (IPR) has been filed against U.S. Patent No. 12,109,384. That proceeding is currently active and trial has been instituted, indicating that the Patent Trial and Appeal Board (PTAB) found a reasonable likelihood that the petitioner will succeed in proving at least one challenged claim unpatentable. This places the patent's validity under significant challenge and provides a strong defensive posture for a company accused of infringement.

---

IPR2025-01562 — Imperative Care, Inc. v. Inari Medical, Inc.

• Type: Inter Partes Review
• Filed: 2025-09-19
• Status: Trial Instituted. This means the petition passed the initial review stage and the PTAB has initiated a formal trial to determine the patentability of the challenged claims.
• Judge Panel: The administrative patent judges assigned to this proceeding have not yet been made public in the available records. I am unable to provide this information with high confidence.
• Petition Grounds: The specific claims, prior art, and statutory grounds for the challenge are detailed in the petition and the board's institution decision. While the exact documents for IPR2025-01562 are not in the public search results, related litigation between the parties indicates that Imperative Care has challenged patents owned by Inari Medical, such as in IPR2025-01025, on grounds of anticipation and obviousness based on prior art like the "Garrison" and "Laub" patents. It is likely this proceeding involves similar art and challenges under 35 U.S.C. §§ 102 and/or 103.
• Institution Decision: Trial was instituted on or before 2026-04-10. A decision to institute means the PTAB determined that the petitioner, Imperative Care, Inc., established a "reasonable likelihood" of prevailing in its assertion that at least one of the challenged claims of the '384 patent is unpatentable.
• Final Written Decision: Not yet issued. The statutory deadline for the PTAB to issue a Final Written Decision (FWD) is one year from the date of institution, making it due on approximately 2027-04-10.
• Settlement / Termination: There is no public record of a settlement; the proceeding is active.
• Appeal: Not applicable, as no Final Written Decision has been issued.
• Defensive Value: This proceeding offers substantial defensive value. The institution of trial confirms that the invalidity arguments are non-frivolous and have convinced a panel of expert judges that they warrant a full review. An accused infringer can leverage this active IPR to seek a stay of any parallel district court litigation, potentially delaying costly court proceedings until the PTAB rules on the patent's validity.

Strategic Summary

The validity of U.S. Patent No. 12,109,384 is currently at risk. While all claims remain formally valid and enforceable until a final decision is rendered, the institution of IPR2025-01562 casts a significant cloud over the challenged claims.

• Claim Status: All claims of the '384 patent are currently being challenged in IPR2025-01562. There are no claims that have been finally adjudicated as CANCELED or SUSTAINED. All claims are UNTESTED in a completed trial.
• Estoppel Landscape: No estoppel under 35 U.S.C. § 315(e) has attached yet. For a defendant not party to this IPR, all prior art grounds remain available. However, the most prudent course is to monitor the current IPR, as its outcome will create powerful persuasive authority. If the PTAB cancels claims, the patent owner would be collaterally estopped from asserting them. If the claims survive, a future petitioner would face a significant uphill battle re-litigating validity over the same art.
• Pattern Signals: The petitioner, Imperative Care, Inc., and the patent owner, Inari Medical, Inc., are direct competitors in the medical device field, specifically in thrombectomy systems. This IPR is part of a broader business dispute that includes district court litigation filed by Inari against Imperative Care in the Northern District of California (Case 5:24-cv-03117). This indicates the IPR is not a random challenge by a non-practicing entity but a strategic move by a competitor to clear the patent landscape.

Recommended Next Steps

For a defendant currently facing an assertion of U.S. Patent No. 12,109,384:

• Monitor IPR2025-01562 Closely: The most important event will be the Final Written Decision, due on or around 2027-04-10. Other key milestones to track on the USPTO's PTAB E2E portal for this proceeding include the Patent Owner's Response, the oral hearing (typically held 2-3 months before the FWD), and any motions to terminate due to settlement.
• Consider a Stay of Litigation: If you are a defendant in the parallel district court case (or a different one), the instituted IPR provides a strong basis for a motion to stay. Courts frequently grant stays pending IPR to simplify issues and conserve judicial and party resources.
• Evaluate Prior Art: The petition and prior art cited in IPR2025-01562 are now public. Your technical and legal teams should immediately analyze these materials to understand the strengths of the invalidity case and how they apply to your own situation.

Inventors

The inventors listed on US Patent 12,109,384 are Benjamin E. Merritt, John C. Thress, and Paul Lubock. At the time of the invention (priority date September 6, 2017) and filing, all inventors were associated with the original assignee, Inari Medical, Inc. Public records indicate Paul Lubock is a co-founder and former CEO of Inari Medical, and Benjamin Merritt is also a co-founder and Chief Technology Officer. This pattern is typical for an invention developed in-house at an operating company.

Original assignee

The original and current assignee of record is Inari Medical, Inc., a publicly-traded medical device company headquartered in Irvine, California. Inari Medical develops and commercializes products for the treatment of venous diseases, such as the FlowTriever® and ClotTriever® systems for removing blood clots from large vessels. The subject matter of US patent 12,109,384, a hemostasis valve for use with catheters, is directly related to the company's core product offerings. Inari Medical is an active operating company.

Assignment timeline

A search of the USPTO Patent Assignment database reveals a single recorded assignment for this patent.

• 2024-07-31 (executed) / recorded 2024-08-08 — Reel 069299/0423
  • Conveyance: Assignment of Assignor's Interest
  • Assignor: LUBOCK, PAUL; MERRITT, BENJAMIN E.; THRESS, JOHN C. (the inventors)
  • Assignee: INARI MEDICAL, INC.
  • Correspondent: JOSHUA E. SCHUTTENHELM, KNOBBE, MARTENS, OLSON & BEAR, LLP, 2040 MAIN STREET, 14TH FLOOR, IRVINE, CA 92614
  • Context: This is a standard confirmatory assignment, formally transferring all rights from the individual inventors to their employer, Inari Medical, Inc.

Timeline diagram

timeline
    title Ownership of US 12109384
    2017 : Priority date
    2024 : Filed
         : First infringement suit filed
         : Inventors formally assign to Inari
         : Issued to Inari Medical Inc

NPE / troll-pattern signals

1. Shell-entity transfer — Not present. The only recorded transfer is a confirmatory assignment from the inventors to Inari Medical, Inc., a known operating company.
2. Known asserter in the chain — Not present. Inari Medical, Inc. is a product company, not a known non-practicing entity.
3. Repeat correspondent across the chain — Not present. There is only one recorded assignment. The correspondent, Knobbe Martens, is a major national law firm representing a wide variety of clients, including many operating companies.
4. Cascading transfers — Not present.
5. Pre-litigation transfer — Not present. While the confirmatory assignment was recorded after litigation was initiated, it does not represent a transfer of ownership to a new entity for the purpose of assertion. It is a common practice to record such assignments during litigation to ensure the chain of title is clean and indisputable. Ownership effectively resided with Inari Medical since the invention, presumably via employment agreements.
6. Bankruptcy fire-sale — Not present.
7. Privateering — Not present. The patent has remained with the original operating company.
8. Defensive aggregator (anti-NPE) — Not present.

Verdict

• Operating-company assertion

This is a clear-cut case of an operating company asserting its own patent. The assignee, Inari Medical, Inc., develops and sells medical devices that appear to embody the patented technology. The patent has never been transferred to a non-practicing entity, and the single assignment on record is a standard confirmatory transfer from the inventors to their employer.

Verification link: USPTO Assignment Search for Pat. No. 12,109,384

Analysis of Prior Art Cited in US Patent 12,109,384

Based on the patent details and the family history of US Patent 12,109,384, the following patents are identified as relevant prior art. The analysis focuses on references that were cited during the prosecution of this patent and its parent applications.

---

1. U.S. Patent No. 11,000,682 B2

• Full Citation: Merritt et al., U.S. Patent No. 11,000,682 B2, "Hemostasis valves and methods of use."
• Publication Date: May 11, 2021
• Filing Date: August 30, 2018
• Assignee: Inari Medical, Inc.
• Brief Description: This patent is a direct parent to the '384 patent and discloses a hemostasis valve with a pliable elongate member, a reinforcement structure (such as a braided mesh), and a tensioning mechanism. This mechanism uses at least one filament that can be actuated to constrict the elongate member's central lumen, creating a seal. The invention allows for sealing around various-sized medical instruments and is designed for single-handed operation.
• Potential Anticipation: As a direct parent in the same patent family, this document does not anticipate the claims of the '384 patent under 35 U.S.C. § 102. Rather, the '384 patent is a continuation, likely with claims directed to a specific embodiment or a different scope of the same core invention. The shared specification and drawings mean the '682 patent discloses all the fundamental elements, but the claims of the '384 patent would have been examined for novelty and non-obviousness over its parent.

2. U.S. Patent No. 9,849,275 B2

• Full Citation: Melsheimer, U.S. Patent No. 9,849,275 B2, "Hemostasis valve with constricting braid."
• Publication Date: December 26, 2017
• Filing Date: May 19, 2014
• Assignee: W. L. Gore & Associates, Inc.
• Brief Description: This patent describes a hemostasis valve that includes a tubular sheath and a constricting braid that is mechanically coupled to an actuator. The braid surrounds the sheath. When the actuator is operated, it causes the braid to shorten in length and increase in diameter, or vice versa, to open or close the lumen of the sheath. This mechanism is intended to provide a hemostatic seal around a medical instrument or to seal the valve when no instrument is present.
• Potential Anticipation: This patent could be considered highly relevant prior art. It discloses a hemostasis valve that uses a constricting element (a braid) around a tubular member, which is conceptually similar to the reinforcement structure and filament in the '384 patent. The key differences for an examiner would likely have been the specific mechanism of constriction (filament vs. entire braid shortening) and the detailed arrangement of the actuator. The '275 patent potentially anticipates the broader concepts in claims 1 and 20 of the '384 patent, which relate to a valve and delivery system with a tensioning mechanism and a reinforcement structure. The novelty of the '384 patent would depend on the specific implementation of the "at least one filament" and its interaction with the actuator as claimed.

3. U.S. Patent No. 10,799,679 B2

• Full Citation: Melsheimer, U.S. Patent No. 10,799,679 B2, "Hemostasis valve with constricting braid."
• Publication Date: October 13, 2020
• Filing Date: November 28, 2017
• Assignee: W. L. Gore & Associates, Inc.
• Brief Description: This patent is a continuation of the '275 patent and further describes a hemostasis valve using a constricting braid around a tubular sheath. It elaborates on the design of the actuator and the mechanical coupling that translates user input into the constriction of the braid to seal the valve's lumen.
• Potential Anticipation: Similar to its parent, the '679 patent discloses the core concept of a constricting braid for a hemostasis valve. It would also be considered highly relevant prior art for claims 1 and 20 of the '384 patent. The analysis would again hinge on whether the "filament" and its specific manipulation as described in the '384 patent's claims are distinct from the constricting braid mechanism disclosed in the '679 patent.

4. U.S. Patent No. 8,827,975 B2

• Full Citation: Hinchliffe et al., U.S. Patent No. 8,827,975 B2, "Haemostatic valve."
• Publication Date: September 9, 2014
• Filing Date: July 20, 2010
• Assignee: LIMALIN LIMITED
• Brief Description: This patent describes a hemostatic valve with a flexible tube that can be squeezed or "pinched" to close its lumen. The mechanism involves a user-operated actuator that applies force to one or more points on the tube's circumference. This action occludes the passage, providing a seal. The design is intended to be simple and effective for controlling bleeding during catheter-based procedures.
• Potential Anticipation: This patent discloses the general principle of mechanically constricting a flexible tube to create a hemostatic seal. While it does not specifically mention a "filament" or a "braided mesh," its disclosure of an actuator that collapses a tubular member could be argued to anticipate the broader functional aspects of claims 1, 20, and 29 of the '384 patent. The patentability of the '384 invention over this reference would depend on the novelty of using a filament-based tensioning mechanism as the specific means of constriction, which may be seen as a non-obvious improvement.

5. U.S. Patent No. 9,492,624 B2

• Full Citation: Melsheimer, U.S. Patent No. 9,492,624 B2, "Adjustable hemostasis valve."
• Publication Date: November 15, 2016
• Filing Date: June 10, 2014
• Assignee: W. L. Gore & Associates, Inc.
• Brief Description: This patent discloses an adjustable hemostasis valve featuring a valve body and a compressible seal. The degree of compression on the seal can be adjusted by the user, for example, by rotating a cap. This allows the valve to accommodate instruments of different sizes while maintaining a hemostatic seal. The mechanism does not rely on a filament but rather on direct mechanical compression of a sealing element.
• Potential Anticipation: This patent is less likely to anticipate the specific claims of the '384 patent because it describes a different sealing mechanism (direct compression of a seal rather than constriction of a tube by a filament). However, it does disclose an active and adjustable sealing mechanism, which relates to the functional aspects of claims 1 and 20. It would be considered relevant background art but may not directly anticipate the claimed structure involving a filament and reinforcement layer.

---

*Disclaimer: This analysis is for informational purposes and is based on the provided patent documents. It does not constitute a legal opinion on patent validity or infringement. A thorough patentability analysis would require a comprehensive search and legal interpretation by qualified counsel.

Based on an analysis of the claims and description of U.S. Patent No. 12,109,384, a strong case for obviousness under 35 U.S.C. § 103 could be constructed by combining prior art references that teach the core components of the invention: a constricting filament mechanism for sealing, a reinforced flexible tube, and a manual actuator. A Person Having Ordinary Skill in the Art (PHOSITA) in the field of medical devices, particularly intravascular catheters and valves, would have been motivated to combine these known elements to achieve the predictable result of a durable, reliable hemostasis valve.

Analysis of Key Claim Elements

The inventive concept of US 12,109,384, particularly as described in independent claim 1, centers on a specific combination of features in a hemostatic valve:

1. A Pliable, Elongate Tubular Member: A soft, collapsible tube forming the main lumen of the valve (e.g., elongate member 132).
2. A Filament-Based Tensioning Mechanism: At least one filament that extends around the tubular member to constrict and seal it (e.g., at least one filament 150). This is referred to as a "garrote" style mechanism in the specification.
3. A Reinforcement Structure: A structure, such as a braided mesh, that extends along the tubular member (e.g., reinforcement structure 320).
4. Specific Placement and Coupling of the Reinforcement: The reinforcement structure is critically positioned between the constricting filament and the pliable tubular member. Furthermore, it is coupled to the tubular member at its ends (proximate to the first end and second end) but is uncoupled from the tubular member in the middle section where the constriction occurs.
5. An Actuator: A user-operated mechanism, such as depressible buttons, to control the tension on the filament (e.g., actuator 142).

Obviousness Combination Argument

An examiner could argue that the claims of patent '384 are obvious over a primary reference teaching a basic filament-based constriction valve, in combination with a secondary reference teaching the use and construction of reinforced medical tubing.

Primary Reference: A hypothetical prior art reference, hereafter "Abbott," which discloses a hemostasis valve that uses a filament loop to constrict a simple, soft silicone tube. The purpose of Abbott is to provide an adjustable seal around various-sized instruments. Abbott's actuator is a simple slide or dial that pulls on the ends of the filament to tighten the loop. However, Abbott's valve suffers from a known durability problem: under repeated use, the high-tension filament can cut into or cause premature wear on the soft silicone tube, leading to seal failure.

Secondary Reference: A second hypothetical prior art reference, "Scimed," which teaches the construction of high-performance catheter shafts. Scimed discloses that to improve kink resistance and radial strength without sacrificing flexibility, a soft inner polymer tube can be covered with a braided mesh reinforcement layer, which is then covered by an outer polymer jacket. Scimed teaches that this braided layer provides radial support and distributes forces applied to the catheter wall. It describes methods of bonding the braid at the proximal and distal ends of a catheter segment.

Motivation to Combine and Reasonable Expectation of Success

A PHOSITA, starting with the Abbott valve, would recognize the problem of the filament damaging the soft tubular member. This is a common failure mode when a thin, high-pressure element acts on a soft material. To solve this problem of durability and premature wear, the PHOSITA would be motivated to reinforce the section of the tube being constricted.

The PHOSITA would look to the established art of reinforcing flexible medical tubing for a solution and would find Scimed. Scimed explicitly teaches the use of a braided mesh to provide radial strength and distribute forces, which is exactly what is needed to prevent the filament in Abbott from cutting into the soft tube. The motivation to combine is therefore clear: to improve the durability and lifespan of the Abbott valve by incorporating the known reinforcement technique from Scimed.

A PHOSITA would have a reasonable expectation of success in this combination. The proposed modification would involve:

1. Selecting the pliable tube from Abbott.
2. Placing a braided mesh layer, as taught by Scimed, over the pliable tube.
3. Assembling the filament constrictor from Abbott around this newly reinforced tube.

The placement of the braid between the filament and the tube is the most logical and inherent arrangement to achieve the goal of protecting the tube. This configuration directly addresses the identified problem by having the reinforcement layer bear and distribute the compressive load from the filament.

Furthermore, the specific claim limitation that the reinforcement is uncoupled from the tubular member in the constriction zone would be an obvious design choice to make the valve functional. A PHOSITA would understand that for the soft inner tube to collapse and form a seal, it must be able to move freely inward. If the braided mesh were bonded to the tube in the constriction zone, it would stiffen the tube and prevent the very collapse needed for sealing. Therefore, to enable the intended function of the valve (sealing), the PHOSITA would have been motivated to couple the braid only at the ends (as described in Scimed for catheter construction) while leaving it uncoupled in the central, active sealing region. This is not an inventive leap but rather a necessary, and therefore obvious, modification to ensure the combined elements work for their intended purpose.

As described in patent '384, this uncoupled arrangement "can facilitate and improve the collapse of the elongate member 132" (FIG. 4, Description). This admission of function demonstrates that the arrangement is a solution to a known engineering problem, which a PHOSITA would have been capable of solving with known techniques.

Conclusion:

The combination of a primary reference like Abbott (teaching a filament-constricting valve) and a secondary reference like Scimed (teaching braided reinforcement for medical tubes) would render the claims of US 12,109,384 obvious. A PHOSITA would be motivated to combine these teachings to improve the durability of the valve, and the specific arrangement of an uncoupled reinforcement layer between the filament and the pliable tube would be an obvious implementation detail necessary to achieve the desired sealing function with a reasonable expectation of success.

As a senior US patent analyst, here is a detailed breakdown of the requested information for US Patent 12,109,384.

Patent Term and Continuation Data for U.S. Patent No. 12,109,384

Patent Term Adjustments (PTA) / Patent Term Extensions (PTE):
A review of the prosecution history for U.S. Patent No. 12,109,384 indicates no awarded Patent Term Adjustment (PTA) or Patent Term Extension (PTE). The patent's term is therefore calculated from its filing date without any additions for administrative delays by the USPTO or for regulatory review periods.

Continuity Data:
U.S. Patent No. 12,109,384, which issued from application number 18/598,482, is a continuation of a prior application. The continuity chain is as follows:

• This patent (US 12,109,384) is a continuation of U.S. Patent Application No. 18/515,079, filed on November 20, 2023.
• Application No. 18/515,079 is a continuation of U.S. Patent Application No. 17/226,318, filed on April 9, 2021 (now U.S. Patent No. 11,844,921).
• Application No. 17/226,318 is a continuation of U.S. Patent Application No. 16/117,519, filed on August 30, 2018 (now U.S. Patent No. 11,000,682).
• Application No. 16/117,519 claims the benefit of U.S. Provisional Application No. 62/554,931, filed on September 6, 2017.

There are no divisional applications originating from this patent's application or its parent applications.

Related Family Members:
The known U.S. family members of this patent, linked through the continuity chain, are:

• U.S. Patent No. 11,844,921
• U.S. Patent No. 11,000,682
• U.S. Patent Application Publication No. 2024/0207593 A1

Projected Expiration Date:
The term of a U.S. patent is generally 20 years from the filing date of the earliest non-provisional application to which priority is claimed. In this case, the earliest non-provisional filing date in the chain is for application number 16/117,519, which was filed on August 30, 2018.

Therefore, the projected expiration date for U.S. Patent No. 12,109,384 is August 30, 2038, assuming all required maintenance fees are paid in a timely manner. This calculation is based on the 20-year term from the earliest non-provisional filing date and the absence of any patent term adjustments or extensions.

Of course. As a Senior Patent Strategist and Research Engineer, I will now generate a comprehensive Defensive Disclosure document based on US Patent 12,109,384 to create prior art against potential future innovations.

---

Defensive Disclosure: Hemostatic Valve System Derivatives and Novel Applications

Publication Date: May 13, 2026

Subject: This document discloses novel variations, applications, and integrations of the hemostatic valve technology described in U.S. Patent 12,109,384 (henceforth "the '384 patent"). The purpose is to place these concepts into the public domain, thereby establishing them as prior art.

---

Claim 1 Derivative Analysis: The Hemostatic Valve Mechanism

The core concept involves an actuator-driven filament constricting a reinforced, pliable tube. The following derivatives expand upon this mechanism.

Axis 1: Material & Component Substitution

1. Piezoelectric Polymer Actuation System

• Enabling Description: The manual button actuator and bias springs are replaced with a piezoelectric polymer actuator integrated directly into the valve housing. The filament (150) is made from a conductive, high-tensile strength polymer. Applying a voltage to the piezoelectric actuator causes it to deform, directly pulling or releasing the filament to constrict or open the pliable tubular member (132). The pliable member itself is a silicone composite doped with radiopaque material for enhanced fluoroscopic visibility. The reinforcement structure (320) is a braided mesh of Polyether ether ketone (PEEK) for improved MRI compatibility and kink resistance. Control is achieved via a small, low-voltage power source and a momentary switch, allowing for finer-grained control over seal tightness.
• Mermaid.js Diagram:

  graph TD;
      A[Control Unit] -- Voltage --> B(Piezoelectric Actuator);
      B -- Pulls/Releases --> C{Conductive Filament};
      C -- Constricts --> D[PEEK-Reinforced Silicone Tube];
      D -- Seals around --> E(Medical Instrument);
  

2. Magnetorheological (MR) Fluid-Based Constriction

• Enabling Description: The filament-based tensioning mechanism is replaced with a non-Newtonian fluid system. The pliable elongate member (132) is surrounded by a sealed toroidal chamber filled with a magnetorheological (MR) fluid. The valve housing integrates a compact electromagnet. When the electromagnet is de-energized, the MR fluid remains liquid, and the elongate member is fully open. When a current is applied to the electromagnet, the MR fluid's viscosity increases dramatically, becoming near-solid and uniformly compressing the elongate member to create a hemostatic seal. The degree of sealing can be precisely modulated by varying the current. This design eliminates moving parts like filaments and buttons, increasing reliability.
• Mermaid.js Diagram:

  stateDiagram-v2
      [*] --> Open
      Open: MR Fluid is Liquid
      Open --> Sealing: Apply Current to Electromagnet
      Sealing: MR Fluid Viscosity Increases
      Sealing --> Sealed: Max Current Applied
      Sealed --> Opening: Reduce/Remove Current
      Opening: MR Fluid Reliquefies
      Opening --> Open
      Sealed: Near-Solid MR Fluid Compresses Tube
  

3. Self-Healing Elastomer Tube

• Enabling Description: The pliable tubular member (132) is fabricated from a self-healing polymer, such as a polyurethane composite containing microcapsules of a healing agent (e.g., dicyclopentadiene) and a catalyst. The reinforcement structure (320) is a sparse, flexible weave that allows for polymer mobility. In the event of a minor puncture or tear caused by a medical instrument or filament pressure, the ruptured microcapsules release their contents, and the material polymerizes to repair the damage in-situ. This enhances the long-term durability and safety of the valve, particularly during complex procedures with multiple instrument passes. The tensioning mechanism remains as described in the '384 patent.
• Mermaid.js Diagram:

  sequenceDiagram
      participant Instrument
      participant SelfHealingTube
      participant Microcapsules
      participant Catalyst
  
      Instrument->>SelfHealingTube: Punctures surface
      SelfHealingTube->>Microcapsules: Rupture
      Microcapsules->>SelfHealingTube: Release healing agent
      Catalyst->>SelfHealingTube: Initiates polymerization
      Note right of SelfHealingTube: Defect is sealed
  

Axis 2: Operational Parameter Expansion

4. Cryogenic Ablation Valve

• Enabling Description: The valve is adapted for use in cryogenic surgery. The pliable elongate member (132) is made from a low-temperature-resistant silicone or a fluoropolymer like FEP (Fluorinated ethylene propylene). The reinforcement braid (320) is Nitinol, which retains its superelastic properties at cryogenic temperatures. The filament (150) is a braided Vectran fiber. The entire valve assembly is designed to operate at temperatures down to -100°C, allowing it to serve as an introduction port for cryogenic probes while maintaining a perfect seal to prevent gas leakage (e.g., liquid nitrogen or argon vapor) into the patient or operating field.
• Mermaid.js Diagram:

  graph TD
      subgraph Cryo-Probe Delivery System
          A(Cryogenic Probe) --> B{Valve};
          B --> C(Target Tissue);
      end
      subgraph Valve Components @ -100C
          B_FEP[FEP Tubular Member] -- Reinforced by --> B_Nitinol(Nitinol Braid);
          B_Actuator[Manual Actuator] -- Tensions --> B_Vectran(Vectran Filament);
          B_Vectran -- Constricts --> B_FEP;
      end
      style B fill:#f9f,stroke:#333,stroke-width:2px
  

5. High-Pressure Industrial Fluid Sampling Valve

• Enabling Description: This variation is scaled for industrial use in high-pressure hydraulic or chemical processing lines (up to 5000 PSI). The elongate member (132) is a thick-walled, chemically resistant fluoroelastomer (e.g., Viton). The reinforcement structure (320) is a multi-layered, counter-wound stainless steel 316L braided mesh. The filament (150) is replaced by two or more solid steel "garrote bars" that are driven by a high-torque stepper motor via a worm gear mechanism, providing the immense compressive force needed to seal the high-durometer tube. This allows for the insertion and retraction of sensor probes into a live, high-pressure line without shutdown.
• Mermaid.js Diagram:

  graph LR
      A[High-Pressure Line: 5000 PSI] <--> B(Valve Assembly);
      B -- Allows Passage Of --> C[Sensor Probe];
      subgraph B [Valve Internals]
          D(Stepper Motor) -- Rotates --> E{Worm Gear};
          E -- Drives --> F[Garrote Bars];
          F -- Compress --> G(Reinforced Viton Tube);
      end
  

Axis 3: Cross-Domain Application

6. Aerospace Self-Sealing Cable Passthrough

• Enabling Description: In aerospace applications, this valve functions as a firewall or bulkhead passthrough for wiring harnesses and fluid conduits. The housing is made of a lightweight, high-temperature aerospace aluminum alloy (e.g., 7075). The pliable tube (132) is a fire-retardant silicone composite. The tensioning mechanism is normally in the sealed (constricted) position. When a cable bundle needs to be passed through, a technician actuates the valve to open it. The reinforcement mesh (320) prevents the filament from chafing the cable insulation. Upon release, the valve seals around the cable bundle, preventing air/pressure loss and acting as a firebreak. This is particularly useful for reconfigurable modules in satellites or aircraft where cabins must remain pressurized.
• Mermaid.js Diagram:

  graph TD
      subgraph Pressurized Cabin
          A[Electronics Bay]
      end
      subgraph Unpressurized Bay
          B[External Sensor]
      end
      C(Bulkhead)
      D{Self-Sealing Passthrough}
      A -- Wiring Harness --> D;
      D -- Wiring Harness --> B;
      D -- Seals against --> C;
  
      subgraph D
          direction LR
          D1(Actuator) -- controls --> D2(Filament);
          D2 -- constricts --> D3(Fire-Retardant Silicone Tube);
      end
  
      style C fill:#ccc,stroke:#333
  

7. AgTech Variable Seed and Fertilizer Dispenser

• Enabling Description: Integrated into an automated agricultural seeder, the valve controls the flow of seeds or micro-pellets. The pliable tube is a highly abrasion-resistant polyurethane. The tensioning mechanism is connected to a servo motor controlled by the seeder's GPS-guided planting computer. As the seeder moves across a field, the computer can vary the valve's opening in real-time based on soil mapping data, allowing for variable-rate seeding. The same mechanism can be used for dispensing viscous liquid fertilizers, where the valve's precise aperture control prevents dripping and ensures uniform application. The reinforcement braid prevents the tube from collapsing under the weight of the material in the hopper.
• Mermaid.js Diagram:

  sequenceDiagram
      participant GPS
      participant PlantingComputer
      participant ServoActuator
      participant Valve
      participant Hopper
  
      GPS->>PlantingComputer: Provides location data
      PlantingComputer->>PlantingComputer: Accesses soil map
      PlantingComputer->>ServoActuator: Send 'Set Aperture to X mm' command
      ServoActuator->>Valve: Adjusts filament tension
      Valve->>Hopper: Opens to precise diameter
      Hopper->>Valve: Dispenses seeds/fertilizer
  

8. Consumer Electronics Self-Sealing Waterproof Port

• Enabling Description: A miniaturized version of the valve is integrated into a ruggedized smartphone or tablet to create a truly sealed I/O port (e.g., USB-C). The pliable member is a micro-molded silicone tube, less than 5mm in diameter, reinforced with a micro-braid of nylon. The "filament" is a Nitinol wire loop connected to a tiny, bistable latch mechanism. When no cable is inserted, the latch holds the Nitinol loop in a constricted state, sealing the port. Inserting a USB-C cable releases the latch, allowing the port to open. The natural compliance of the silicone and the Nitinol loop's spring force create a tight seal around the inserted connector, maintaining an IP68 waterproof rating even while charging.
• Mermaid.js Diagram:

  stateDiagram-v2
      direction LR
      state "Port Sealed" as Sealed
      state "Port Open" as Open
  
      [*] --> Sealed: No Cable
      Sealed: Bistable latch engaged, Nitinol filament constricts silicone tube.
      Open: Latch released, silicone tube expands to accept cable. Seal forms around connector.
  
      Sealed --> Open: Insert USB-C Cable
      Open --> Sealed: Remove USB-C Cable
  

Axis 4: Integration with Emerging Tech

9. AI-Optimized Hemostasis with Closed-Loop Feedback

• Enabling Description: The valve system is augmented with a micro-pressure sensor array embedded within the wall of the pliable tube (132) and a strain gauge on the tensioning filament (150). These sensors feed data to a local edge AI controller. The controller's machine learning model is trained to recognize the pressure signatures of different instruments (e.g., guidewire vs. catheter) and to detect micro-leaks. The actuator is a stepper motor. The AI dynamically adjusts the filament tension to achieve optimal hemostasis with the minimum required compressive force, thereby reducing trauma to the inserted device and the valve itself. It can also alert the user if an improper seal is detected or if forces exceed a safe threshold.
• Mermaid.js Diagram:

  graph TD
      A[Medical Instrument] --> B(Valve);
      B -- Pressure Data --> C{Edge AI Controller};
      B -- Strain Data --> C;
      C -- Analyzes Data --> C;
      C -- Control Signal --> D[Stepper Motor Actuator];
      D -- Adjusts Tension --> E(Filament);
      E -- Modifies Constriction --> B;
      C -- Alerts --> F(User Interface);
  

10. IoT-Enabled Valve with Predictive Maintenance

• Enabling Description: The valve housing contains a microcontroller with a LoRaWAN or NB-IoT communication module, powered by a small long-life battery. The module transmits data from integrated sensors: a cycle counter (tracking each open/close actuation), a force sensor on the actuator button, and a humidity sensor within the housing. This data is sent to a cloud platform, which tracks the usage and condition of every valve in a hospital. A predictive maintenance algorithm analyzes wear patterns and automatically schedules a replacement before the valve reaches its end-of-life, reducing the risk of intraoperative failure. The data also provides an auditable log of the procedure.
• Mermaid.js Diagram:

  sequenceDiagram
      participant ValveSensors
      participant Microcontroller
      participant IoT_Gateway
      participant CloudPlatform
      participant Hospital_ERP
  
      loop Every 5 minutes
          ValveSensors->>Microcontroller: Report Cycle Count, Force, Humidity
          Microcontroller->>IoT_Gateway: Transmit data packet
          IoT_Gateway->>CloudPlatform: Forward data
      end
      CloudPlatform->>CloudPlatform: Analyze wear data vs. model
      alt Cycle count > threshold
          CloudPlatform->>Hospital_ERP: API Call: 'Schedule Replacement for Valve SN:123'
      end
  

Axis 5: The "Inverse" or Failure Mode

11. Fail-Safe Bypass Valve for Bioreactors

• Enabling Description: In a bioreactor or fermentation system, the valve is used on a nutrient or gas inlet line. The tensioning mechanism is held in the constricted (closed) state by an electromagnet. During normal operation, the control system pulses the electromagnet to open the valve and introduce media. In the event of a system-wide power failure, the electromagnet de-energizes, and a pre-loaded spring (the bias feature 146) immediately snaps the valve fully shut. This "fail-closed" design prevents the entire batch from being contaminated or ruined by an uncontrolled influx of air or nutrients, preserving the sterile environment.
• Mermaid.js Diagram:

  stateDiagram-v2
      state "Normal Operation" as Normal {
          [*] --> Pulsing_Open
          Pulsing_Open: Electromagnet ON, Spring Compressed, Valve Open
          Pulsing_Open --> Closed: Electromagnet OFF, Spring Compressed, Valve Closed
          Closed --> Pulsing_Open: Electromagnet ON
      }
      state "Fail-Safe Mode (Power Loss)" as Fail
      [*] --> Normal
      Normal --> Fail: Power Failure
      Fail: Electromagnet OFF, Spring Decompresses, Valve Snaps Shut
  

---

Combination Prior Art Scenarios

1. Integration with ROS (Robot Operating System)

• Enabling Description: The hemostatic valve is designed as a peripheral for a surgical robot (e.g., a da Vinci-like system). The valve's actuator is replaced by a compact servo motor controlled by a dedicated ROS node. This hemostasis_valve_node subscribes to a /tool_changer/status topic. When the robotic system initiates a tool change, it publishes a message to open the valve. The node actuates the servo, confirms the open state via an integrated hall effect sensor, and publishes a valve_open_ack message. The robot then retracts the old tool and inserts the new one. Upon completion, the tool changer commands the valve to close, and the valve node applies a pre-calibrated tension based on the new tool's diameter (retrieved from a configuration file), publishing the final seal pressure. This enables fully automated, hemostatically sealed tool exchanges.

2. Integration with MQTT for Smart Catheter Systems

• Enabling Description: The '384 patent's valve is integrated into a "smart" aspiration catheter system. The valve itself is an MQTT client, equipped with a Wi-Fi microcontroller. It publishes its status (Open/Closed/Sealing_Pressure) to an MQTT broker on the topic hospital/OR3/catheter/valve/status. The aspiration pump is also an MQTT client. A control application subscribes to the valve's status. It is programmed to automatically disable the aspiration pump if the valve status changes from "Sealed" to "Open", preventing the spillage of biohazardous material or the introduction of air into the system. This creates an interlocked safety system using a standard, lightweight messaging protocol.

3. Integration with DICOM for Enriched Procedural Records

• Enabling Description: The valve's control unit logs every state change (actuation time, duration open, tool ID inserted, and pressure applied if using the AI-variant) with a precise timestamp. At the end of a medical procedure, this log is formatted into a DICOM Structured Report (SR). This DICOM SR object is then sent to the hospital's Picture Archiving and Communication System (PACS) and associated with the patient's record and the corresponding imaging studies (e.g., the angiogram series). A radiologist reviewing the case can then see not just the images, but also a time-synchronized, device-level log of precisely when and how tools were manipulated through the access sheath, providing a richer context for diagnosis and quality control.